E Pitfalls Of Biotechnology Investing

Investing in biotechnology companies is difficult. One has to understand the science behind the drugs to start with. Then understand the patent landscape, the clinical use of the drug, clinical standard of care, regulatory pathway with the FDA, and competition from existing and upcoming new therapies. This is in addition to standard items one looks at in a company such as management, cash flow, payor reimbursement, etc.. But one item that gets little attention, but which skews the offerings of biotechnology companies to begin with, is the role investors play in the very establishment of these firms

Biotechnology companies start with either capital from 3F (friends, family, and fools), Angels, rare early-stage VC, or specialized outfits such as those from Universities. The latter three are particularly subject to the vagaries of investing. 

The first problem is the disease area focus. These come and go, which is a problem since drug development takes such a long time. One area may be the flavor du jour only to disappear a few years later. Right now, immune-oncology is the darling child and almost everything else is an orphan, particularly anti-bacterial drugs. So the money goes predominantly into companies in the immune-oncology space while others, even if needed and deserving, are neglected. This leads to misallocation of resources which ultimately leads to too many drugs chasing too few opportunities (in the chosen field) while others wither on grapevine. When the reckoning comes, a whole slew of companies lose money, and so do investors, who promise never to fund biotechnology again.

The second problem is related to the first – what appears “sexy”. Often, drugs that are prohibitively expensive to use are still developed because they are “sexy”. Antibodies, anti-sense therapies, stem cells, are all in vogue at the moment. How an antibody can be used for a disease like osteoarthritis beggars the commercial mind. We have already seen antibodies that were developed for hypercholesterolemia become commercial failures, despite great fanfare at launch (by Regeneron and Amgen). The market could simply not afford such expensive medications when cheaper alternatives are available, and the incremental benefit does not justify the cost.

1 2
View single page >> |
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
George Lipton 2 months ago Member's comment

Good summary of some of the issues in this industry. With this in mind, why did you choose to focus on this space.

Ketan Desai 2 months ago Author's comment

Thanks. Since I have been the founder of more than one biotechnology company, I'm keenly interested and aware of the issues facing this sector.